These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28744992)

  • 1. The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial.
    Elbarbary NS; Ismail EAR; El-Naggar AR; Hamouda MH; El-Hamamsy M
    Pediatr Diabetes; 2018 May; 19(3):470-477. PubMed ID: 28744992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial.
    Siriwattanasit N; Satirapoj B; Supasyndh O
    BMC Nephrol; 2021 Jun; 22(1):236. PubMed ID: 34174842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin B complex supplementation as a homocysteine-lowering therapy for early stage diabetic nephropathy in pediatric patients with type 1 diabetes: A randomized controlled trial.
    Elbarbary NS; Ismail EAR; Zaki MA; Darwish YW; Ibrahim MZ; El-Hamamsy M
    Clin Nutr; 2020 Jan; 39(1):49-56. PubMed ID: 30704890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial.
    Sattarinezhad A; Roozbeh J; Shirazi Yeganeh B; Omrani GR; Shams M
    Diabetes Metab; 2019 Jan; 45(1):53-59. PubMed ID: 29983230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Khatami PG; Soleimani A; Sharifi N; Aghadavod E; Asemi Z
    J Clin Lipidol; 2016; 10(4):922-929. PubMed ID: 27578124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial.
    Bahmani F; Kia M; Soleimani A; Mohammadi AA; Asemi Z
    Br J Nutr; 2016 Oct; 116(7):1222-1228. PubMed ID: 27647263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acids supplementation improves early-stage diabetic nephropathy and subclinical atherosclerosis in pediatric patients with type 1 diabetes: A randomized controlled trial.
    Elbarbary NS; Ismail EAR; Mohamed SA
    Clin Nutr; 2023 Dec; 42(12):2372-2380. PubMed ID: 37862823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.
    Houjeghani S; Kheirouri S; Faraji E; Jafarabadi MA
    Nutr Res; 2018 Jan; 49():96-106. PubMed ID: 29420997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Coenzyme Q10 Supplementation on Glucose Metabolism, Lipid Profiles, Inflammation, and Oxidative Stress in Patients With Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Gholnari T; Aghadavod E; Soleimani A; Hamidi GA; Sharifi N; Asemi Z
    J Am Coll Nutr; 2018; 37(3):188-193. PubMed ID: 29111905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of vitamin D supplementation on lipid profiles and oxidative indices among diabetic nephropathy patients with marginal vitamin D status.
    Barzegari M; Sarbakhsh P; Mobasseri M; Noshad H; Esfandiari A; Khodadadi B; Gargari BP
    Diabetes Metab Syndr; 2019; 13(1):542-547. PubMed ID: 30641762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study.
    Karkabounas S; Papadopoulos N; Anastasiadou C; Gubili C; Peschos D; Daskalou T; Fikioris N; Simos YV; Kontargiris E; Gianakopoulos X; Ragos V; Chatzidimitriou M
    J Med Food; 2018 Dec; 21(12):1197-1203. PubMed ID: 30311825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
    Alkhalaf A; Klooster A; van Oeveren W; Achenbach U; Kleefstra N; Slingerland RJ; Mijnhout GS; Bilo HJ; Gans RO; Navis GJ; Bakker SJ
    Diabetes Care; 2010 Jul; 33(7):1598-601. PubMed ID: 20413516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects.
    Soleimani A; Zarrati Mojarrad M; Bahmani F; Taghizadeh M; Ramezani M; Tajabadi-Ebrahimi M; Jafari P; Esmaillzadeh A; Asemi Z
    Kidney Int; 2017 Feb; 91(2):435-442. PubMed ID: 27927601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin.
    Hasslacher C; Kulozik F
    J Diabetes; 2016 Sep; 8(5):712-9. PubMed ID: 26615054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.